Research and Markets: In January 2006, Teva Completed Its Acquisition of IVAX, Further Strengthening Teva's Global Presence

Business Wire, April 24, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36063) has announced the addition of the Espicom Business Intelligence report "Teva Generics Company Intelligence Report" to their offering.

Teva Pharmaceutical Industries has its headquarters in Israel; it was incorporated in Israel in 1944, and is the successor to a number of Israeli corporations, the oldest of which was established in Jerusalem in 1901. In 1951, Teva, as one of the first industrial companies in Israel, raised funds through an initial public offering on the Tel Aviv stock exchange. In 1964, Assia and Zori, two Israeli drug firms, merged and later acquired a controlling interest in Teva. The three firms formally merged in 1976, becoming Teva Pharmaceutical Industries.

In 1982, Teva first entered the US market, after gaining FDA approval for its manufacturing site. At the same time, Teva commenced trading its American Depository Receipts on the NASDAQ market. In 1985, a joint company was set up between Teva and the US' WR Grace. Lemmon, a small Pennsylvania-based generic manufacturer, was acquired in 1986. During the 1990s, Teva bought out WR Grace's interest in the joint venture. The 1990s also saw Teva move into the European market, and the launch of Teva's proprietary multiple sclerosis product, Copaxone.

In 2000, Teva acquired Canada's Novopharm, which led to Teva becoming the largest generic pharmaceutical company in North America. The company continued to expand its global presence, acquiring Teva Classics (previously Bayer) in France, and the Honeywell Fine Pharmaceutical Chemical plants in northern Italy (since renamed Teva PFC) in 2002. In 2004, Teva acquired Sicor, another US generic firm with a generic injectable business and a biogenerics capability.

In January 2006, Teva completed its acquisition of IVAX, further strengthening Teva's global presence, and ensuring the company's position as the largest generic pharmaceutical firm in the world. As a result, Teva now operates directly in over 50 countries, and employs in the region of 25,000 people.

This generics company report will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. This informative report provides an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Key topics covered include:

Products

Teva Generic Companies Analysis

Financial Results

Major Developments

Generic Companies Analysis Teva

For more information visit http://www.researchandmarkets.com/reports/c36063